Pyxis Oncology, Inc. PYXS 深 滬
等待開盤 08-05 09:30:00 美东时间
1.10
0.000
0.00%
華盛通- 最 高1.14
- 今 開1.10
- 成交量 24.21万股
- 最 低 1.09
- 昨 收 1.10
- 總市值 6814.25万
- 52周最高 5.3899
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.8332
- 委 比 60.97%
- 總股本 6194.77万
- 歷史最高 19.00
- 量 比 1.19
- 振 幅 4.55%
- 歷史最低 0.8332
- 每 手 1
- 風險率 1.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pyxis Oncology Updates Enrollment for Phase 1 Trial of New Cancer Drug Micvo
On July 31, 2025, revisions to patient enrollment participants related to Pyxis Oncology, Inc.'s (the "Company") Phase 1 monotherapy clinical trial to evaluate micvotabart pelidotin ("MICVO", formerly PYX-201) were made
08-04 19:29
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 30, 2025 – Pyxis Oncology granted stock options to purchase 246,238 shares to four new employees under its 2022 Inducement Plan. The options have a $1.10 exercise price, with 181,238 shares vesting over four years and 65,000 shares vesting by December 31, 2025. Pyxis Oncology is a clinical-stage company developing innovative treatments for difficult cancers, focusing on its lead candidate, micvotabart pelidotin (MICVO), currently in ...
06-30 20:30
美股大行评级 | 摩根大通：维持网易"超配"评级，目标价升至135美元；瑞银上调达美航空评级至"买入"
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1131517965561573377.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Armata Pharmaceuticals(ARMP)"买入"评级，目标价从7美元升至9美元</p> <p>• 瑞银：维持爱芬奇(ANF)"买入"评级，目标价从115美
05-20 09:28
HC Wainwright & Co. Reiterates Buy on Pyxis Oncology, Maintains $5 Price Target
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Pyxis Oncology (NASDAQ:PYXS) with a Buy and maintains $5 price target.
05-19 18:55
美股大行评级 | Compass Point：上调Affirm Holdings评级至"买入"，目标价从61美元升至64美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109399410911752193.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Femasys Inc Ordinary Shares(FEMY)"买入"评级，目标价从12美元升至15美元</p> <p>• HC Wainwright & C
03-20 09:49
Pyxis Oncology Advances Cancer Therapeutics with MICVO
Pyxis Oncology, Inc. ( ($PYXS) ) has released its Q4 earnings. Here is a breakd...
03-19 11:55
Pyxis Oncology Announces CMO Resignation and New Trials
The latest announcement is out from Pyxis Oncology ( ($PYXS) ). On March 18, 20...
03-18 20:15
Pyxis Oncology FY 2024 GAAP EPS $(1.32) Misses $(1.09) Estimate, Sales $16.15M Beat $13.81M Estimate
Pyxis Oncology (NASDAQ:PYXS) reported quarterly losses of $(1.32) per share which missed the analyst consensus estimate of $(1.09) by 21.1 percent. This is a 28.65 percent increase over losses of $(1.85) per share from
03-18 19:33
Top-rated biotechs with negative enterprise values
After four consecutive years of underperformance, biotech stocks are among the most unloved segments in the market. Major industry benchmarks SPDR S&P Biotech ETF (NYSEARCA:XBI) and the iShares Biotec...
03-02 03:28
Pyxis Oncology rises on FDA fast track tag for lead asset
Shares of Pyxis Oncology (NASDAQ:PYXS) traded higher in the premarket on Wednesday after the U.S. FDA issued its Fast Track Designation for the company’s lead candidate, PYX-201, targeted at head and ...
02-26 20:55
